Genomic Variant Interpretation
Interpret genomic variants by querying ClinVar, gnomAD, COSMIC, and other curated genomic databases. This skill provides ACMG/AMP-aligned pathogenicity classification, population frequency analysis, clinical significance assessment, and actionability evaluation for germline and somatic variants identified through clinical genomic testing.
Quick Install
npx skills add Open-Medica/open-medical-skills --skill genomics-variant-interpreter
What It Does
- ACMG/AMP classification framework: Applies the American College of Medical Genetics and Genomics (ACMG) / Association for Molecular Pathology (AMP) five-tier classification system (Pathogenic, Likely Pathogenic, Variant of Uncertain Significance, Likely Benign, Benign) with documented supporting criteria codes (PVS1, PS1-4, PM1-6, PP1-5, BA1, BS1-4, BP1-7)
- Multi-database cross-referencing: Queries ClinVar for curated pathogenicity assertions and review status, gnomAD for population allele frequencies across diverse ancestries, COSMIC for somatic mutation frequency in cancer types, and OMIM for gene-disease associations
- Population frequency analysis: Compares variant allele frequency across gnomAD populations (African, East Asian, European, Latino, South Asian) to identify ancestry-specific considerations and assess rarity using BA1 and BS1 frequency thresholds
- Somatic variant annotation: For tumor-derived variants, provides COSMIC prevalence data, known driver/passenger classification, associated cancer types, and tier-level evidence for therapeutic relevance using the AMP/ASCO/CAP somatic variant classification system
- Clinical actionability assessment: Links pathogenic/likely pathogenic variants to ClinGen-curated gene-disease validity classifications and actionability scores, identifying which findings warrant clinical intervention, surveillance, or cascade family testing
Clinical Use Cases
- Germline genetic testing interpretation: A genetic counselor receives whole exome sequencing results for a patient with a family history of hereditary breast/ovarian cancer. The skill interprets a BRCA2 variant, pulling ClinVar consensus (pathogenic, 4-star review status), gnomAD frequency (<0.0001), and NCCN management recommendations
- Tumor profiling analysis: An oncologist receives next-generation sequencing results from a solid tumor panel. The skill classifies each somatic variant by AMP/ASCO/CAP tier, identifies Tier I variants with FDA-approved companion diagnostics, and flags Tier II variants with clinical trial eligibility
- Pharmacogenomic variant interpretation: A clinical pharmacologist needs to interpret CYP2D6 star allele combinations. The skill translates diplotype results into metabolizer phenotype predictions and links to CPIC dosing guidelines for affected medications
- Variant reclassification monitoring: A molecular diagnostics lab re-evaluates a VUS reported two years ago. The skill checks for new ClinVar submissions, published functional studies, and updated population frequency data that may support reclassification
Safety & Evidence
- Safety Classification: Restricted — Genomic variant interpretation directly influences clinical decision-making including surgical prophylaxis (e.g., risk-reducing mastectomy for BRCA carriers), targeted therapy selection, reproductive planning, and cascade family testing. All interpretations must be reviewed and signed out by a board-certified molecular pathologist or clinical geneticist. Variants of uncertain significance must never be used as the sole basis for clinical action. This skill provides interpretive support, not final clinical reports.
- Evidence Level: High — Classification follows ACMG/AMP standards (Richards et al., 2015), somatic interpretation follows AMP/ASCO/CAP guidelines (Li et al., 2017), and all database annotations are sourced from expert-curated repositories (ClinVar, ClinGen, gnomAD). However, variant interpretation is an evolving field and classifications may change as new evidence emerges.
Example Usage
Germline variant interpretation:
Interpret variant: NM_000059.4(BRCA2):c.5946delT (p.Ser1982ArgfsTer22)
Clinical context: 38-year-old female with family history of breast cancer
(mother diagnosed at 42, maternal aunt at 45)
Variant Interpretation:
Variant: BRCA2 c.5946delT (p.Ser1982ArgfsTer22)
Type: Frameshift deletion causing premature termination codon
ACMG Classification: Pathogenic
Evidence supporting pathogenicity:
- PVS1 (Very Strong): Null variant (frameshift) in BRCA2, a gene where loss of function is a known disease mechanism
- PS1 (Strong): Same amino acid change previously established as pathogenic in ClinVar (87 submissions, 4-star review status, all concordant pathogenic)
- PM2 (Moderate): Absent from gnomAD population databases (0/251,354 alleles)
- PP1 (Supporting): Co-segregates with disease in multiple affected families in published literature
gnomAD frequency: Not observed (0.000000)
ClinVar: Pathogenic (4-star consensus, 87 submitters)
OMIM: Associated with Hereditary Breast-Ovarian Cancer Syndrome (OMIM #612555)
Clinical actionability:
- Refer to cancer genetics for comprehensive risk assessment
- NCCN recommends enhanced breast surveillance (annual MRI + mammography starting at age 25) and discussion of risk-reducing surgery
- Cascade genetic testing recommended for at-risk first-degree relatives
- Ovarian cancer risk management per NCCN guidelines
Technical Details
- Category: Clinical Research Summarizing
- Author: OMS Contributors
- License: MIT
- Version: 1.0.0
- Specialty: Medical Genetics, Genomics
References
- Richards S, et al. "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP." Genet Med. 2015;17(5):405-424.
- Li MM, et al. "Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of AMP, ASCO, and CAP." J Mol Diagn. 2017;19(1):4-23.
- ClinVar database (NCBI) — ncbi.nlm.nih.gov/clinvar/
- gnomAD (Genome Aggregation Database) — gnomad.broadinstitute.org
- ClinGen Clinical Genome Resource — clinicalgenome.org
- COSMIC (Catalogue of Somatic Mutations in Cancer) — cancer.sanger.ac.uk/cosmic
This skill is part of Open Medical Skills, a curated marketplace of medical AI skills maintained by physicians for physicians and the healthcare industry.
1---2name: genomics-variant-interpreter3description: Interpret genomic variants using ClinVar, gnomAD, and other genomic databases. Provides pathogenicity classification and clinical significance assessment.4---56# Genomic Variant Interpretation78Interpret genomic variants by querying ClinVar, gnomAD, COSMIC, and other curated genomic databases. This skill provides ACMG/AMP-aligned pathogenicity classification, population frequency analysis, clinical significance assessment, and actionability evaluation for germline and somatic variants identified through clinical genomic testing.910## Quick Install1112```bash13npx skills add Open-Medica/open-medical-skills --skill genomics-variant-interpreter14```1516## What It Does1718- **ACMG/AMP classification framework**: Applies the American College of Medical Genetics and Genomics (ACMG) / Association for Molecular Pathology (AMP) five-tier classification system (Pathogenic, Likely Pathogenic, Variant of Uncertain Significance, Likely Benign, Benign) with documented supporting criteria codes (PVS1, PS1-4, PM1-6, PP1-5, BA1, BS1-4, BP1-7)19- **Multi-database cross-referencing**: Queries ClinVar for curated pathogenicity assertions and review status, gnomAD for population allele frequencies across diverse ancestries, COSMIC for somatic mutation frequency in cancer types, and OMIM for gene-disease associations20- **Population frequency analysis**: Compares variant allele frequency across gnomAD populations (African, East Asian, European, Latino, South Asian) to identify ancestry-specific considerations and assess rarity using BA1 and BS1 frequency thresholds21- **Somatic variant annotation**: For tumor-derived variants, provides COSMIC prevalence data, known driver/passenger classification, associated cancer types, and tier-level evidence for therapeutic relevance using the AMP/ASCO/CAP somatic variant classification system22- **Clinical actionability assessment**: Links pathogenic/likely pathogenic variants to ClinGen-curated gene-disease validity classifications and actionability scores, identifying which findings warrant clinical intervention, surveillance, or cascade family testing2324## Clinical Use Cases2526- **Germline genetic testing interpretation**: A genetic counselor receives whole exome sequencing results for a patient with a family history of hereditary breast/ovarian cancer. The skill interprets a BRCA2 variant, pulling ClinVar consensus (pathogenic, 4-star review status), gnomAD frequency (<0.0001), and NCCN management recommendations27- **Tumor profiling analysis**: An oncologist receives next-generation sequencing results from a solid tumor panel. The skill classifies each somatic variant by AMP/ASCO/CAP tier, identifies Tier I variants with FDA-approved companion diagnostics, and flags Tier II variants with clinical trial eligibility28- **Pharmacogenomic variant interpretation**: A clinical pharmacologist needs to interpret CYP2D6 star allele combinations. The skill translates diplotype results into metabolizer phenotype predictions and links to CPIC dosing guidelines for affected medications29- **Variant reclassification monitoring**: A molecular diagnostics lab re-evaluates a VUS reported two years ago. The skill checks for new ClinVar submissions, published functional studies, and updated population frequency data that may support reclassification3031## Safety & Evidence3233- **Safety Classification:** Restricted — Genomic variant interpretation directly influences clinical decision-making including surgical prophylaxis (e.g., risk-reducing mastectomy for BRCA carriers), targeted therapy selection, reproductive planning, and cascade family testing. All interpretations must be reviewed and signed out by a board-certified molecular pathologist or clinical geneticist. Variants of uncertain significance must never be used as the sole basis for clinical action. This skill provides interpretive support, not final clinical reports.34- **Evidence Level:** High — Classification follows ACMG/AMP standards (Richards et al., 2015), somatic interpretation follows AMP/ASCO/CAP guidelines (Li et al., 2017), and all database annotations are sourced from expert-curated repositories (ClinVar, ClinGen, gnomAD). However, variant interpretation is an evolving field and classifications may change as new evidence emerges.3536## Example Usage3738**Germline variant interpretation:**39```40Interpret variant: NM_000059.4(BRCA2):c.5946delT (p.Ser1982ArgfsTer22)41Clinical context: 38-year-old female with family history of breast cancer42(mother diagnosed at 42, maternal aunt at 45)43```44> **Variant Interpretation:**45>46> **Variant:** BRCA2 c.5946delT (p.Ser1982ArgfsTer22)47> **Type:** Frameshift deletion causing premature termination codon48> **ACMG Classification:** Pathogenic49>50> **Evidence supporting pathogenicity:**51> - PVS1 (Very Strong): Null variant (frameshift) in BRCA2, a gene where loss of function is a known disease mechanism52> - PS1 (Strong): Same amino acid change previously established as pathogenic in ClinVar (87 submissions, 4-star review status, all concordant pathogenic)53> - PM2 (Moderate): Absent from gnomAD population databases (0/251,354 alleles)54> - PP1 (Supporting): Co-segregates with disease in multiple affected families in published literature55>56> **gnomAD frequency:** Not observed (0.000000)57> **ClinVar:** Pathogenic (4-star consensus, 87 submitters)58> **OMIM:** Associated with Hereditary Breast-Ovarian Cancer Syndrome (OMIM #612555)59>60> **Clinical actionability:**61> - Refer to cancer genetics for comprehensive risk assessment62> - NCCN recommends enhanced breast surveillance (annual MRI + mammography starting at age 25) and discussion of risk-reducing surgery63> - Cascade genetic testing recommended for at-risk first-degree relatives64> - Ovarian cancer risk management per NCCN guidelines6566## Technical Details6768- **Category:** Clinical Research Summarizing69- **Author:** OMS Contributors70- **License:** MIT71- **Version:** 1.0.072- **Specialty:** Medical Genetics, Genomics7374## References7576- Richards S, et al. "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP." *Genet Med*. 2015;17(5):405-424.77- Li MM, et al. "Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of AMP, ASCO, and CAP." *J Mol Diagn*. 2017;19(1):4-23.78- ClinVar database (NCBI) — ncbi.nlm.nih.gov/clinvar/79- gnomAD (Genome Aggregation Database) — gnomad.broadinstitute.org80- ClinGen Clinical Genome Resource — clinicalgenome.org81- COSMIC (Catalogue of Somatic Mutations in Cancer) — cancer.sanger.ac.uk/cosmic8283---8485*This skill is part of [Open Medical Skills](https://github.com/Open-Medica/open-medical-skills), a curated marketplace of medical AI skills maintained by physicians for physicians and the healthcare industry.*